Scinovex
article Open Access

Nanovaccine approach to prevent binding of SARS-CoV-2 surface glycoprotein with ACE2 and TMPRSS2 receptor

Abstract

The present worldwide health risk through the COVID-19 needs a quick arrangement of modern therapeutic strategies available. The role of nanomedicine is highly suitable against this “entity”. Nano interference is argued in terms of developing significant nanocarriers to counter the standard barriers of antiviral and biological therapeutics. This way promotes the safe and possible delivery of available therapeutic strategies by modified nanocarriers, inhibiting the primary interactions of spike glycoprotein to host cell surface receptors, and disturb vision formation. Controlling and terminating the spread and reappearance of this pandemic commands a safe and beneficial vaccine options. Nanocarriers have probable to outline risk-free and possible immunization ways for SARS-CoV-2 vaccine candidates like protein constructs and nucleic acids.

SARS-CoV-2 and COVID-19 ResearchLipid Membrane Structure and BehaviorNanoparticle-Based Drug DeliveryTMPRSS2Coronavirus disease 2019 (COVID-19)GlycoproteinSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Virology2019-20 coronavirus outbreakReceptorComputational biologyBiologyMedicine

Funding

  • Visvesvaraya National Institute of Technology
Citations
0
FWCI
0.00
field-weighted impact
References
0
Percentile
7%
vs. same field & year
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.